Skip to main content

Resverlogix Corp(RVX-T)
TSX

Today's Change
Real-Time Last Update

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Globe Newswire - Wed Jun 8, 2022

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators” in the journal Biomedicine & Pharmacotherapy. The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe